Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Treasury Shares (2017 - 2025)

Moleculin Biotech (MBRX) has 8 years of Treasury Shares data on record, last reported at $407381.0 in Q4 2024.

  • For Q4 2024, Treasury Shares rose 333.87% year-over-year to $407381.0; the TTM value through Dec 2024 reached $407381.0, up 333.87%, while the annual FY2024 figure was $407381.0, 333.87% up from the prior year.
  • Treasury Shares reached $407381.0 in Q4 2024 per MBRX's latest filing, up from $93895.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $16.4 million in Q1 2020 and bottomed at $40499.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $4.3 million, with a median of $313970.0 recorded in 2021.
  • Peak YoY movement for Treasury Shares: crashed 94.24% in 2020, then surged 333.87% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $98482.0 in 2020, then soared by 123.96% to $220559.0 in 2021, then plummeted by 81.64% to $40499.0 in 2022, then skyrocketed by 131.85% to $93895.0 in 2023, then surged by 333.87% to $407381.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $407381.0 in Q4 2024, $93895.0 in Q4 2023, and $40499.0 in Q4 2022.